Key result
Intraarterial infusion of the ETA receptor antagonist BQ-123 attenuated radial artery vasoconstriction during reduced blood flow compared to saline.
Why the study?
Does intraarterial infusion of an ETA receptor antagonist reduce vasoconstriction of large conduit arteries during reduced flow in healthy subjects?
Does intraarterial infusion of an ETA receptor antagonist reduce vasoconstriction of large conduit arteries during reduced flow in healthy subjects?
ETA receptor activation mediates active vasoconstriction of large conduit arteries during reduced blood flow, suggesting a potential therapeutic role for ETA receptor antagonism in low-flow disease states.
Answers are grounded in this paper and cite their sources.
No immediate clinical role for ETA antagonists; leaves open their mechanistic contribution to low-flow vasoconstriction.
Vascular tone is regulated by endothelium-derived vasodilating and constricting substances, mainly nitric oxide and endothelin (ET)-1. These 2 mediators, which antagonize the actions of each other, are released in response to shear-stress produced by blood flow. The aim of this study was to delineate the contribution of endogenous ET-1 on vascular tone of a large conduit artery during reduced and hyperemic flow. Radial artery diameter was continuously measured with a high-resolution ultrasonic echo-tracking device in 8 healthy subjects. After establishing stable baseline conditions, a wrist cuff was inflated to suprasystolic pressure for 5 minutes. In another 5 subjects, measurements were obtained during intraarterial infusion of saline or an ETA receptor antagonist (BQ-123, 1 nmol/min) in a dosage not affecting basal radial diameter. Wrist occlusion caused a progressive vasoconstriction of the radial artery (P = 0.0001). Vasoconstriction of the radial artery during wrist occlusion was significantly attenuated by ETA receptor antagonism (-2.7% +/- 0.6% versus -6.8% +/- 0.6% during saline, P = 0.007). Flow-mediated vasodilation was not influenced by BQ-123 (7.5% +/- 0.8% versus 7.8% +/- 1.1%, P = NS). This study demonstrates active vasoconstriction of large conduit arteries during conditions of reduced blood flow via ETA receptoractivation. This may play an important role in disease states with reduced systemic or local blood flow and indicates the therapeutic potential of ETA receptor antagonism.
No takes yet. Share an insight, caveat, or question.
Spieker et al. (2003) studied Healthy (n=13). ETA receptor antagonist (BQ-123) vs. Saline was evaluated on Vasoconstriction of the radial artery during wrist occlusion (p=0.007). Intraarterial infusion of the ETA receptor antagonist BQ-123 attenuated radial artery vasoconstriction during reduced blood flow compared to saline.
Synapse has enriched 10 related papers. Consider them for comparative context: